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Incidence of Atazanavir-associated Hyperbilirubinemia in Korean 
HIV Patients: 30 Months Follow-up Results in a Population with 
Low UDP-glucuronosyltransferase1A1*28 Allele Frequency
Hyperbilirubinemia is frequently observed in Caucasian HIV patients treated with 
atazanavir. UDP-glucuronosyltransferase 1A1 polymorphism, UGT1A1*28, which is 
associated with atazanavir-induced hyperbilirubinemia, is less common in Asians than in 
Caucasians. However, little is known about the incidence of atazanavir-associated 
hyperbilirubinemia in Asian populations. Our objective was to investigate the incidence of 
and tolerability of atazanavir-associated hyperbilirubinemia in Korean HIV patients. The 
prevalence and cumulative incidence of atazanavir-associated hyperbilirubinemia and 
UGT1A1*28 allele frequency was investigated in 190 Korean HIV-infected patients treated 
with atazanavir 400 mg per day. The UGT1A1*28 were examined by direct sequencing of 
DNA from peripheral whole blood. The UGT1A1*28 allele frequency was 11%. The 
cumulative incidence of any grade of hyperbilirubinemia was 77%, 89%, 98%, and 100%, 
at 3, 12, 24, and 30 months, respectively. The cumulative incidence of severe (grade 3–4) 
hyperbilirubinemia was 21%, 41%, 66%, and 75%, at 3, 12, 24, and 30 months, respectively. 
However, the point prevalence of severe hyperbilirubinemia did not increase with time and 
remained around 25%. Our data suggest that atazanavir-associated hyperbilirubinemia is 
common but transient in a population with low UGT1A1*28 allele frequency.
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INTRODUCTION
Atazanavir is an HIV protease inhibitor with several advantages 
including once-daily dosing, low pill burden, and a favorable 
effect on lipid profile compared with other protease inhibitors 
(1, 2). Unconjugated hyperbilirubinemia is the major laborato-
ry abnormality associated with use of atazanavir (3). Although 
atazanavir-associated hyperbilirubinemia is not associated with 
hepatic injury (3), it may be a hurdle in actual clinical practice 
because it can cause cosmetic concerns (1).
  Atazanavir induces hyperbilirubinemia by competitive inhi-
bition of the microsomal enzyme UDP-glucuronosyltransferase 
(UGT) 1A1, which is responsible for bilirubin conjugation (4, 5). 
Promoter containing seven thymine adenine (TA) nucleotide 
repeats, A(TA)7TAA (the UGT1A1*28 allele), is less active than 
the common promoter containing 6 TA repeats (6). Homozy-
gosity for the UGT1A1*28 allele is strongly associated with the 
risk of developing hyperbilirubinemia while receiving atazana-
vir (5, 7).
  The frequency of the UGT1A1*28 allele differs between racial 
groups. Its frequency is much lower in Asians including Japa-
nese (11%), Chinese (16%), and Koreans (13%), than in other 
racial groups such as African Americans (43%), Caucasians (36–
39%), and Indians (35%) (8-11). Therefore, the incidence of clin-
ically significant hyperbilirubinemia associated with atazanavir 
might be expected to be lower in Asians than in other racial 
groups. However, previous studies of atazanavir-associated hy-
perbilirubinemia were based on Caucasians, Hispanic, and Af-
rican populations, and to our knowledge, there has been no re-
port focusing on Asian populations. Hence, in this study, we in-
vestigated the incidence and tolerability of atazanavir-associat-
ed hyperbilirubinemia in Korean HIV patients.
 
MATERIALS AND METHODS
Patients
All the HIV-infected patients who initiated antiretroviral thera-
py with atazanavir (400 mg per day) from May 2005 to April 2007 Choe PG, et al.  •  Atazanavir-associated Hyperbilirubinemia in Koreans 
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were identified from the electronic database of Seoul National 
University Hospital (SNUH). Patients with active liver disease 
were excluded. Total bilirubin levels and HIV viral titers in blood 
were measured every 3 months after initiating atazanavir. Sub-
jects who did not discontinue atazanavir were followed up until 
April 2008. Antiretroviral therapy regimen was managed by the 
board certified infectious disease specialist. 
Data collection and definition
Atazanavir-associated hyperbilirubinemia was defined as a hy-
perbilirubinemia developing after initiation of atazanavir ther-
apy in the absence of other cause of hyperbilirubinemia. Hy-
perbilirubinemia was classified in accordance with the AIDS 
Clinical Trials Group guidelines for total bilirubin levels: grade 
1, 23–32 μM/L (1.3–1.9 mg/dL); grade 2, 33–53 μM/L (1.9–3.1 
mg/dL); grade 3, 54–105 μM/L (3.1–6.1 mg/dL); and grade 4, 
>105 μM/L (>6.1 mg/dL) (12). Viral suppression was defined as 
<40 copies/mL. Active liver disease was defined as an elevation 
of hepatic transaminase to more than 2 times the upper limit of 
normal. 
UGT1A1*28 analysis
The recognition of TA repetitions at the UGT1A1 promoter gene 
was assessed by direct sequencing of DNA extracted from pe-
ripheral whole blood, using previously reported primers and 
PCR conditions (4).
Statistics
Continuous variables are expressed as median and interquar-
tile range (IQR) values. The confidence intervals of the occur-
rence rates of hyperbilirubinemia were estimated from Poisson 
distribution 95% confidence limits. Proportions were compared 
using the chi-square test. Statistical analyses were performed 
with SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA).
Ethics statement
The study protocol was approved by the SNUH Institutional 
Review Board (IRB No. H-0710-008-221). Informed consent 
was waived by the IRB.
RESULTS
Study population
One hundred and ninety HIV-infected patients were included 
in this study. Total follow-up duration was 3,511 person-months, 
and median duration of atazanavir treatment was 17 months 
(IQR, 12–27 months). 
  All were Koreans, and 173 (91.1%) of the patients were male. 
The median age was 41 yr (IQR, 34–53 yr). The median CD4 cell 
count at the beginning of atazanavir therapy was 258 cells/μL 
(IQR, 160-413 cells/μL), and 61 (32.1%) patients were antiretro-
viral naïve patients. Atazanavir containing regimen accounted 
for 34.3% of initial combination regimens for the antiretroviral-
naïve patients during the study period. Antiretroviral drugs that 
were administered concurrently with atazanavir included zid-
ovudine/lamivudine (n=146, 76.8%), stavudine+lamivudine 
(n=24, 12.6%), abacavir+lamivudine (n=12, 6.3%), didanosine+ 
lamivudine (n=7, 3.7%), and zidovudine+didanosine (n=1, 0.5%). 
The genetic study was performed in 168 (88.4%) of these patients 
and the distribution of UGT1A1 genotypes was as follows: TA6/
TA6 in 78.0%, TA6/TA7 in 21.4%, and TA7/TA7 in 0.6% (Table 1).
Incidence of hyperbilirubinemia
The data on total bilirubin levels was available in 1,143 (97.7%) 
of 1,170 bilirubin measurements which were expected during 
3,511 person-months follow-up period. The cumulative inci-
dence of hyperbilirubinemia of any grade was 76.8% (95% con-
fidence interval [CI], 70.1–82.4) at 3 months, 89.3% (95% CI, 
83.3–93.4) at 12 months, 98.6% (95% CI; 91.9–100) at 24 months, 
and 100% (95% CI, 90.9–100) at 30 months. The cumulative in-
cidence of grade 3-4 hyperbilirubinemia was 21.4% (95% CI, 
16.0–28.1) at 3 months, 41.3% (95% CI; 33.8–49.3) at 12 months, 
64.4% (95% CI, 52.9–74.4) at 24 months, and 74.5% (95% CI, 
57.0–84.0) at 30 months. Although the cumulative incidence of 
grade 3–4 hyperbilirubinemia increased consistently with time, 
the prevalence of grade 3–4 hyperbilirubinemia at specific time 
points remained around 25% (Fig. 1). There was no significant 
difference in prevalence of hyperbilirubinemia between total 
patients and those with viral suppression at each time point 
(P=0.57).
  In the 91 patients who experienced grade 3–4 hyperbilirubi-
nemia during the study period, the median time from atazana-
vir initiation to detection of grade 3–4 hyperbilirubinemia was 6 
months (range 1–27 months). Grade 3–4 hyperbilirubinemia 
Table 1. Baseline characteristics of the study participants
Characteristics     Study participants (N=190)
Male sex, n (%) 173 (91.1)
Age, median years (IQR) 41 (34-53)
Presumed HIV transmission route, n (%)
   MSM
   Heterosexual sex
   Blood product
   IV drug user
   Unknown
71 (37.4)
61 (32.1)
5 (2.6)
0 (0)
53 (27.9)
CD4 cell count, median cells/µL (IQR) 258 (160-413)
Viral load, log10 copies/mL (IQR) 3.74 (1.39-4.90)
Total bilirubin, median mg/dL (IQR) 0.7 (0.6-1.0)
Positive for hepatitis C antibodies, n (%) 9 (4.7)
Positive for hepatitis B antigen, n (%) 12 (6.3)
UGT1A1*28 allele frequency, n (%)*
   TA6/TA6
   TA6/TA7
   TA7/TA7
131 (78.0)
36 (21.4)
1 (0.6)
*Of these patients, 168 (88.4%) were tested for UGT1A1*28 genotype. 
IQR, inter-quartile range; MSM, men who have sex with men.Choe PG, et al.  •  Atazanavir-associated Hyperbilirubinemia in Koreans 
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developed more than 3 months after atazanavir initiation in 53 
(58.2%) patients, and more than 1 yr in 17 (18.7%) patients. Of 
the latter 17 patients, 15 (88.2%) maintained the viral suppressed 
state before the development of grade 3–4 hyperbilirubinemia.
  Among the 40 patients who were followed up to 30 months, 
29 (72.5%) developed grade 3-4 hyperbilirubinemia. Of these, 
grade 3–4 hyperbilirubinemia was persistent during the study 
period in only one (3.4%), while it was transient in the other 28 
(96.6%) patients.
Discontinuation of atazanavir
Of the 190 patients, 54 (28.4%) discontinued atazanavir therapy 
during the study period. The most common reason for discon-
tinuation was loss to follow-up (18 patients; 9.5%), followed by 
viral resistance to atazanavir (14 patients; 7.4%), and cosmetic 
problem due to hyperbilirubinemia (11 patients; 5.8%). Atazana-
vir therapy was discontinued in eight (21.1%) of 38 patients in 
whom grade 3–4 hyperbilirubinemia developed within 16 weeks 
after initiating atazanavir, and in three (5.7%) of 53 patients in 
whom it developed after 16 weeks (P=0.034).
 
DISCUSSION
Koreans have a lower frequency of the UGT1A1*28 allele (9- 
10), which is significantly associated with grade 3-4 hyperbili-
rubinemia in patients taking atazanavir (5). It might be suppos-
ed therefore that the incidence of atazanavir-associated hyper-
bilirubinemia would be lower in Koreans than in Caucasians. 
However, contrary to this expectation, the incidence of grade 
3-4 hyperbilirubinemia in Korean HIV patients with long-term 
atazanavir use was similar or even higher than in Caucasians. 
Among our patients who had taken atazanavir for more than 12 
months, 41.3% developed grade 3-4 hyperbilirubinemia. After 
24 months of atazanavir treatment, 64.4% of patients experienced 
grade 3-4 hyperbilirubinemia. The present study showed higher 
incidences of grade 3-4 hyperbilirubinemia than those reported 
in the clinical trials using an unboosted atazanavir regimen in 
Caucasian patients (3, 13). The incidences at 12 months and 24 
months were equal to those reported in the clinical trials using 
boosted atazanavir regimen (14, 15). 
  In previous studies on Caucasians, bilirubin elevation was 
detected within the 12-16 weeks of treatment initiation in ma-
jority of subjects with grade 3-4 hyperbilirubinemia (3, 7, 13-
15). However, in the present study, the median duration from 
atazanavir initiation to detection of grade 3-4 hyperbilirubine-
mia was 6 months. Although in patients with delayed-onset hy-
perbilirubinemia, drug adherence might influence onset of hy-
perbilirubinemia, its effect was supposed to be minimal be-
cause most the patients in this study achieved complete viral 
suppression. 
  The clinical course of grade 3-4 hyperbilirubinemia also dif-
fered from the results of previous studies in Caucasians. In the 
studies in Caucasian, grade 3-4 hyperbilirubinemia persisted 
throughout the atazanavir treatment (3, 13-15). However, in our 
study, grade 3-4 hyperbilirubinemia was transient in spite of 
continued atazanavir treatment. This was compatible with the 
findings that although the cumulative incidence of grade 3-4 
hyperbilirubinemia increased steadily over the observed peri-
ods, the cross-sectional prevalence of grade 3-4 hyperbilirubi-
nemia remained around 25%. 
  Although atazanavir-associated hyperbilirubinemia is not 
associated with hepatic injury, it may lead to cosmetic concerns 
that result in discontinuation of atazanavir (1). In the clinical 
trials, the cosmetic concerns appeared to be well tolerated by 
subjects and led to treatment discontinuation in less than 1% (3, 
13-15). In the present study, 11 (5.8%) patients discontinued ata-
zanavir therapy because of jaundice. Interestingly, hyperbiliru-
binemia detected after 16 weeks was better tolerated than hy-
perbilirubinemia before 16 weeks, in part because delayed-on-
set hyperbilirubinemia was generally transient.
  There are some limitations to the present study. First, factors 
other than atazanavir could have affected bilirubin metabolism. 
To reduce the effect of possible confounders, we excluded pa-
tients with active liver disease, which might influence bilirubin 
metabolism. Second, when investigating the point prevalence 
of hyperbilirubinemia, patients who discontinued atazanavir 
were excluded; therefore our prevalence data might have un-
derestimated the actual prevalence of hyperbilirubinemia.
  In summary, more than two-thirds of Korean patients who 
received atazanavir for two years experienced grade 3–4 hyper-
bilirubinemia in actual clinical practice. This suggests that severe 
atazanavir-associated hyperbilirubinemia is frequent in Asian 
population with low UGT1A1*28 prevalence. A further study to 
find out the genetic factors other than UGT1A1*28 for atazana-
vir-associated hyperbilirubinemia in Asians is warranted.
Fig. 1. Prevalence and cumulative incidence of grade 3-4 hyperbilirubinemia in Koreans 
HIV patients taking unboosted atazanavir.
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